Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | HPRT1 | P00492 | 13/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3878324 | 0.86 | CYP3A4 (0.35) | CYP3A4HPRT1SMN1; SMN2 | |
| SCHEMBL4364337 | 0.82 | CDK1 (0.36) | SMN1; SMN2 | |
| SCHEMBL28492789 | 0.81 | CYP3A4 (0.42) | CYP3A4HPRT1TYMPSMN1; SMN2 | |
| SCHEMBL2824954 | 0.81 | CYP3A4 (0.42) | CYP3A4HPRT1TYMPSMN1; SMN2 | |
| SCHEMBL4241363 | 0.81 | PDPK1 (0.42) | CYP3A4FGFR1 | |
| SCHEMBL2250902 | 0.80 | FGFR1 (0.40) | CYP3A4FGFR1HPRT1SLC22A6TYMP | |
| SCHEMBL7165315 | 0.77 | CDK1 (0.31) | — | |
| SCHEMBL6334774 | 0.77 | HPRT1 (0.34) | CYP3A4FGFR1HPRT1SLC22A6 | |
| SCHEMBL9621984 | 0.75 | CDK1 (0.33) | — | |
| SCHEMBL6267281 | 0.74 | USP2 (0.30) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0647272-B1 | ANTI-HIV PROTEINS GAP 31, DAP 30 AND DAP 32, DNA CODING THEREFOR AND THERAPEUTIC USES THEREOF | UNIV NEW YORK (US) | 2003-07-30 | — | — | EP | claimed |
| EP-0647272-A1 | ANTI-HIV PROTEINS GAP 31, DAP 30 AND DAP 32, DNA CODING THEREFOR AND THERAPEUTIC USES THEREOF | NEW YORK UNIVERSITY (US) | 1995-04-12 | — | — | EP | claimed |
| EP-0647272-A4 | ANTI-HIV PROTEINS GAP 31, DAP 30 AND DAP 32, DNA CODING THEREFOR AND THERAPEUTIC USES THEREOF. | UNIV NEW YORK (US) | 1994-10-20 | — | — | EP | claimed |
| WO-1993004085-A1 | ANTI-HIV PROTEINS GAP 31, DAP 30 AND DAP 32, DNA CODING THEREFOR AND THERAPEUTIC USES THEREOF | NEW YORK UNIVERSITY (US) | 1993-03-04 | — | — | WO | claimed |
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-06-18 | — | — | US | disclosed |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | IDENIX PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2006130217-A2 | SUBSTITUTED PHOSPHATE ESTERS OF NUCLEOSIDE PHOSPHONATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-0837677-B1 | BROMINATED HEXAHYDROXYBIPHENYL DERIVATIVES | UNIV NORTH CAROLINA (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-0857018-B1 | BETULINIC ACID DERIVATIVES AND USES THEREFOR | UNIV NORTH CAROLINA (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1397957-A2 | Betulinic acid derivatives and uses therefor | The University of North Carolina at Chapel Hill (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-0647272-B1 | ANTI-HIV PROTEINS GAP 31, DAP 30 AND DAP 32, DNA CODING THEREFOR AND THERAPEUTIC USES THEREOF | UNIV NEW YORK (US) | 2003-07-30 | — | — | EP | disclosed |
| EP-0857018-A4 | BETULINIC ACID DERIVATIVES AND USES THEREFOR | UNIV NORTH CAROLINA (US) | 2002-10-23 | — | — | EP | disclosed |
| US-5312837-A | Method of treating viral infections with aryl macrocyclic compounds | GENELABS TECHNOLOGIES, INC. (US) | 1994-05-17 | — | — | US | disclosed |
| WO-1994003164-A1 | INHIBITION AND TREATMENT OF INFECTION BY ENVELOPED VIRUS WITH CALIX(N) ARENE COMPOUNDS | GENELABS TECHNOLOGIES, INC. (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0569533-A1 | ARYL MACROCYCLIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 1993-11-18 | — | — | EP | disclosed |
| WO-1993018763-A1 | COMPOSITIONS OF N-(PHOSPHONOACETYL)-L-ASPARTIC ACID AND METHODS OF THEIR USE AS BROAD SPECTRUM ANTIVIRALS | U.S. BIOSCIENCE, INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| US-5196452-A | Macrocyclic anti-viral compound and method | GENELABS INCORPORATED (US) | 1993-03-23 | — | — | US | disclosed |
| WO-1993004085-A1 | ANTI-HIV PROTEINS GAP 31, DAP 30 AND DAP 32, DNA CODING THEREFOR AND THERAPEUTIC USES THEREOF | NEW YORK UNIVERSITY (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5166173-A | Macrocyclic chromotropic sulfur acids with polar substituents | GENELABS INCORPORATED (US) | 1992-11-24 | — | — | US | disclosed |
| WO-1992012709-A1 | ARYL MACROCYCLIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156545-A1 | Substituted Phosphate Esters of Nucleoside Phosphonates | PNP, TYMP, ENPP1 | CYP3A4 3081/4885FGFR1 1039/4885HPRT1 73/4885 |
| US-20080261913-A1 | Phosphoroamidate conjugated to therapeutic agent such as Aclarubicin; nucleoside derivatives; S-pivaloyl-2-thioethyl phosphoroamidate; liver cancer, inflammation, fibrosis, metabolic disorders | NTPCR, PNP, TYMP | CYP3A4 3582/4885FGFR1 876/4885HPRT1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.